Colon cancer in patients 40 years old or younger

Similar documents
COLORECTAL CANCER SCREENING

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

Colonoscopy Data Collection Form

Early Colonoscopy in Patients with Acute Diverticulitis Simon Bar-Meir, M.D.

Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University

Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes. Dr. med. Henrik Csaba Horváth

The Forzani MacPhail Colon Cancer Screening Centre Frequently Asked Questions. What is the Forzani MacPhail Colon Cancer Screening Centre?

Epi procolon The Blood Test for Colorectal Cancer Screening

Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins

Rare Thoracic Tumours

Together, The Strength

Colorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

A new score predicting the survival of patients with spinal cord compression from myeloma

The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006

Chapter 14 Cancer of the Cervix Uteri

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)

ESD for colorectal lesions I am in favour. Alessandro Repici, MD Digestive Endoscopy Unit IRCCS Istituto Clinico Humanitas Milano, Italy

Bridging Techniques. What s between EMR and Traditional Surgery? Elisabeth C. McLemore, MD, FACS, FASCRS

Prognostic impact of uric acid in patients with stable coronary artery disease

Colorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society

Multiple Primary and Histology Site Specific Coding Rules KIDNEY. FLORIDA CANCER DATA SYSTEM MPH Kidney Site Specific Coding Rules

CURRICULUM VITAE DONALD B. COLVIN, M.D., FACS, FASCRS. Fairfax Colon and Rectal Surgery 2710 Prosperity Ave. Suite #200 Fairfax, VA

Colorectal cancer. A guide for journalists on colorectal cancer and its treatment

Colorectal Cancer Care A Cancer Care Map for Patients

SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD

Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?

Laparoscopic Surgery of the Colon and Rectum (Large Intestine) A Simple Guide to Help Answer Your Questions

Survival analysis of 220 patients with completely resected stage II non small cell lung cancer

Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation

Cancer of the Cardia/GE Junction: Surgical Options

Colon Cancer. What Is Colon Cancer? What Are the Screening Methods?

Cervical Cancer The Importance of Cervical Screening and Vaccination

The recommendations made throughout this book are by the National Health and Medical Research Council (NHMRC).

The Hereditary Colorectal Cancer Website has been sponsored by the Robert Rauschenberg Foundation

Table 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA

Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up

Early mortality rate (EMR) in Acute Myeloid Leukemia (AML)

OBJECTIVES By the end of this segment, the community participant will be able to:

Colon and Rectal Cancer

Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization N = 50

Cystic Neoplasms of the Pancreas: A multidisciplinary approach to the prevention and early detection of invasive pancreatic cancer.

Business Loan Insurance Plan Critical Illness Claim - Policy 57903

Use of stents in esophageal cancer" Hans Gerdes, M.D. Director, GI Endoscopy Unit Memorial Sloan-Kettering Cancer Center

9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH

Bowel cancer: should I be screened?

Prostate cancer statistics

Survivorship Care Plans Guides for Living After Cancer Treatment

Squamous Cell Carcinoma of Anal Canal Treatment Guidelines

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy

Laparoscopic Colectomy. What do I need to know about my laparoscopic colorectal surgery?

There are many different types of cancer and sometimes cancer is diagnosed when in fact you are not suffering from the disease at all.

Bowel Preparation for Colon Resection. Eric Klein, M.D. SUNY Downstate Department of Surgery

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Cancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients?

Breast Imaging Made Brief and Simple. Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA

Stage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center

Endometrial Cancer Treatment

The PSA Test for Prostate Cancer Screening:

Official reprint from UpToDate UpToDate

Billing Guideline. Subject: Colorectal Cancer Screening Exams (Invasive Procedures) Effective Date: 1/1/2012 Last Update Effective: 4/16

Example 1 is the Chart Audit Form. A few comments about the items are:

Why I don t recommend endometrial ablation

Introduction Objective Methods Results Conclusion

PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT

Chapter 2 History of MD Anderson s Tumor Registry

Frequently Asked Questions About Ovarian Cancer

Sinus Headache vs. Migraine

Big Data and Oncology Care Quality Improvement in the United States

THINGS TO BE AWARE OF ABOUT PROSTATE AND LUNG CANCER. Lawrence Lackey Jr., M.D. Internal Medicine 6001 W. Outer Dr. Ste 114

Survey of Mesothelioma Associated with Asbestos Exposure in Japan

As Reported by the Senate Health, Human Services and Aging Committee. 127th General Assembly Regular Session Sub. S. B. No A B I L L

Tips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD

Outcome analysis of breast cancer patients who declined evidence-based treatment

BOWEL CANCER. The doctor has explained that you have a growth or tumour, in your bowel or rectum and could be cancer.

Prostate Cancer Screening

PROTOCOL OF THE RITA DATA QUALITY STUDY

Testing for Prostate Cancer. Should I be tested? Is it the right choice for me?

Guide to Abdominal or Gastroenterological Surgery Claims

Transcription:

BUMC Proceedings 1998;11:175-178 Colon cancer in patients 40 years old or younger ROBERT E. FARNER, MD, TAMMY L. FISHER, RN, ROBERT M. JACOBSON, MD, PAITOON TULANON, MD, EDWARD R. FRANKO, MD, R. D. DIGNAN, MD, JOSEPH A. KUHN, MD, AND WARREN E. LICHLITER, MD Departments of Surgery and Colon and Rectal Surgery, BUMC This report examines risk factors and survival outcomes in 64 patients aged 40 years or younger (mean = 34) with colorectal adenocarcinoma seen in a single institution from 1986 to 1996. Bleeding and pain were the most common symptoms. Risk factors identified in 31 (48%) of the patients included inflammatory bowel disease, familial polyposis, family history of colorectal cancer, and/or family history of polyposis. The stage at presentation determined overall 5-year survival. There was no stage or survival difference for patients with inflammatory bowel disease, family history, or mucinous tumors. Pain was a significant prognostic indicator for stage of cancer. There were increased risk ratios for male patients, those with polyps, and those with poorly differentiated tumors. denocarcinoma of the colon and rectum is the second leading cause of cancer-related deaths in the USA. Approximately 155,000 new cases of colorectal cancer and an estimated 60,000 deaths from this disease are reported each year (1-3). Estimates are that 2% to 6% of these cases are diagnosed in patients 40 years old or younger (1-3). Considerable debate remains regarding treatment and prevention of colorectal cancer in this young age group and is due, in part, to the limited number of cases reported. In addition, some contend that this age group has a more advanced stage of cancer at the time of diagnosis (2-8), while others question whether these patients have a worse survival outcome compared with the older population (4, 8). The current study examines prognostic factors and survival in patients 40 years old or younger with colorectal cancer. METHODS A retrospective study was performed on data from 64 patients diagnosed with colorectal cancer who were 40 years old or younger. These patients had been treated at Baylor University Medical Center (BUMC) between 1986 and 1996. The data reviewed were obtained from hospital medical records, individual physician office records, operative reports, and pathology reports. Follow-up information was obtained from clinical charts, personal contact, and written correspondence. For each patient, age, symptoms on presentation at BUMC, premalignant factors, family history, and tumor characteristics were obtained. Premalignant factors assessed included inflammatory bowel disease, familial polyposis, and history of polyps. Family factors included colon cancer, polyps, and familial polyposis. Tumor characteristics assessed were

location, depth, size, number, and histologic findings. The Aster-Coller modified Dukes classification was used for classifying the stage of cancer in each patient. Statistical analyses also were performed. Age, sex, symptoms, premalignant factors, family history, and tumor characteristics were analyzed univariately using the Mantel-Haenszel chi-square test to determine significance towards presenting stage and 5-year survival. Multivariate analysis of these factors on 5-year survival was calculated using the Cox proportional hazards model test. Survival curves were obtained with the Kaplan-Meier method, and significance was analyzed with the log-rank test. Comparison between these younger patients and the general population's stage of cancer and 5-year survival was performed using data from the National Cancer Data Base of the American College of Surgeons' Commission on Cancer (9). RESULTS In the 10-year period studied (1986 1996), 64 patients 40 years old or under were diagnosed at BUMC with adenocarcinoma of the colon and rectum: 28 were male and 36 were female. The patients' ages ranged from 16 to 40 years (mean = 34 years). Follow-up time ranged from 0.3 to 10.5 years (mean = 4.5 years). Inflammatory bowel disease was reported in 17% of the patients, familial polyposis in 16%, and a history of polyps in 14%. Thirteen percent of the patients had a family history of colon cancer; 11%, familial polyposis; and 8%, polyps. The most common presenting symptoms were bleeding (71%), pain (30%), weight loss >10 pounds (19%), and bowel obstruction (6%). Well-differentiated or moderately differentiated histology was present in 80% of the patients. Only 14% of the cancers were mucinous. Synchronous lesions were found in 11% of the patients, and there were no metachronous lesions. Patients with well-differentiated or moderately differentiated histology had a significantly increased survival (P =.03; Figure 1), whereas there was no significant difference in survival between patients with mucinous and those with nonmucinous tumors (Figure 2). As indicated in Figure 3, 16% of the tumors were located in the right colon, 8% in the transverse area, 13% in the left region, 26% in the sigmoid colon, and 37% in the rectum. There were no significant differences between location of the tumor and 5-year survival (Figure 4). According to the Aster-Coller modified Dukes classification, 20% of the patients were stage A, 23% were stage B, 30% were stage C, and 27% were stage D. Analysis of the relation between these data and the 5-year survival rate revealed that the more advanced the stage of cancer, the lower the survival (P =.001; Figure 5). Pain was the only presenting symptom found to be significantly related to cancer stage (P =.004; Figure 6). Those patients <30 years old had a significantly increased survival compared with those aged 30 to 40 years (P =.02; Figure 7). There was no significant relation between history of inflammatory bowel disease and survival in these younger patients (Figure 8).

Male patients, patients with a history of polyps, and patients with poorly differentiated tumors had an increased risk ratio (Table). Patients with synchronous lesions had a decreased risk ratio. Using the National Cancer Data Base of the American College of Surgeons, a comparison was made between colorectal cancer in the general population and this younger patient group. No statistical difference, however, was found between stages of cancer and stagerelated survival (Figures 9 and 10). DISCUSSION In this study, bleeding, pain, and weight loss were the most common symptoms in patients 40 years old or younger with colorectal cancer. Most studies have found that there is no correlation between symptoms and cancer stage (2, 3, 8, 10). In contrast, pain was shown to be a significant indicator of more advanced disease in this study. Duration of symptoms did not have significant predictive value for either stage of cancer or survival. When age, sex, and premalignant symptoms were assessed univariately for correlation with 5-year survival, age was the only factor associated with 5-year survival. When all of the factors were analyzed together, significant correlations were found between male patients and 5-year survival, and patients with polyps and 5-year survival. It has long been thought that in order for younger patients to develop colorectal cancer, premalignant factors, such as a history of polyps, familial polyposis, or inflammatory bowel disease, had to be present. However, in this study <40% of the patients had any of these factors. One consistent finding between this study and previous studies was that the presenting stages of cancer and 5-year survival were similar in patients both with and without inflammatory bowel disease (2, 3, 5, 8). Both univariate and multivariate analyses found well-differentiated and moderately differentiated cancers to have a significantly better 5-year survival than poorly differentiated cancers. Unlike other larger studies, this study did not reveal an increased percentage of younger patients with poorly differentiated cancers or a correlation between these cancers and mucin production (2). Mucin-producing tumors have long been thought to be a factor of poorly differentiated cancers, with decreased survival rates. This factor, however, was not found to be of significance to either cancer stage or 5-year survival in this and in a number of other studies (2, 3). Cancer stage was found to be the strongest indicator of 5-year survival. A number of other studies indicate that younger colorectal cancer patients present with more

advanced disease (2, 4, 5, 8). The present study, compared with the National Cancer Data Base, does not support this conclusion. As with most reports of survival rates for patients with colorectal cancer, patients 40 years of age or younger with this disease appear to have 5-year survival rates that are similar to those of patients with colorectal cancer who are older than 40 (2, 3, 6, 10, 11). References 1. Cascinu S, Del Ferro E, Grianti C, Ligi M, Catalano G: S-phase fraction and tumor aneuploidy in colorectal carcinoma of young patients. Cancer 1996;78:1857-1860. 2. Cusack JC, Giacco GG, Cleary K, Davidson BS, Izzo F, Skibber J, Yen J, Curley SA: Survival factors in 186 patients younger than 40 years old with colorectal adenocarcinoma. J Am Coll Surg 1996;183:105-112. 3. Lee PY, Fletcher WS, Sullivan ES, Vetto JT: Colorectal cancer in young patients: characteristics and outcome. Am Surg 1994;60:607-612. 4. Behbehani A, Sakwa M, Ehrlichman R, Maguire P, Friedman S, Steele GD Jr, Wilson RE: Colorectal carcinoma in patients under age 40. Ann Surg 1985;202:610 614. 5. Heimann TM, Oh C, Aufses AH Jr: Clinical significance of rectal cancer in young patients. Dis Colon Rectum 1989;32:473-476. 6. Heimann TM, Martinelli G, Szporn A, Kurtz RJ, Quish A, Miller F, Oh SC, Fasy T: Prognostic significance of DNA content abnormalities in young patients with colorectal cancer. Ann Surg 1989;210:792-795. 7. Lundy J, Welch JP, Berman M: Colorectal cancer in patients under 40 years of age. J Surg Oncol 1983;24:11-14. 8. Noack MM, Hernandez E: Colorectal carcinoma in the young patient. Surgical Rounds 1996;19:529-534. 9. Steele GD Jr: The National Cancer Data Base report on colorectal cancer. Cancer 1994;74:1979-1989. 10. Adloff M, Arnaud JP, Schloegel M, Thibaud D, Bergamaschi R: Colorectal cancer in patients under 40 years of age. Dis Colon Rectum 1986;29:322-325. 11. Ohman U: Colorectal carcinoma in patients less than 40 years of age. Dis Colon Rectum 1982;25:209-214.

Figure 1 Figure 2 Figure 3 Figure 4

Figure 5 Figure 6 Figure 7 Figure 8

Figure 9 Figure 10